One of these cell lines had a KRAS mutation only without a PI3K pathway mutation (HEC50), and the antagonism of the combinations may possibly be partly as a result of the particularly marked anti-tumour efficacy of MEK inhibition alone in this cell line. This evidence concerns the gene MAP2K7 and neoplasm.